Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).

Article  PubMed  Google Scholar 

Will, M., Liang, J., Metcalfe, C. & Chandarlapaty, S. Therapeutic resistance to anti-oestrogen therapy in breast cancer. Nat. Rev. Cancer 23, 673–685 (2023).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mottamal, M., Kang, B., Peng, X. & Wang, G. From pure antagonists to pure degraders of the estrogen receptor: evolving strategies for the same target. ACS Omega 6, 9334–9343 (2021).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liang, J. et al. GDC-9545 (giredestrant): a potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast cancer. J. Med. Chem. 64, 11841–11856 (2021).

Article  PubMed  CAS  Google Scholar 

Liang, J. et al. Giredestrant counters a progesterone hypersensitivity program driven by estrogen receptor mutations in breast cancer. Sci. Transl. Med. 14, eabo5959 (2022).

Article  PubMed  CAS  Google Scholar 

Martín, M. et al. Giredestrant for estrogen receptor-positive, HER2-negative,previously treated advanced breast cancer: results from the randomized, phase II acelERA Breast Cancer Study. J. Clin. Oncol 42, 2149–2160 (2024).

Article  PubMed  Google Scholar 

Toy, W. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45, 1439–1445 (2013).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Robinson, D. R. et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 1446–1451 (2013).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jeselsohn, R. et al. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin. Cancer Res. 20, 1757–1767 (2014).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schiavon, G. et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci. Transl. Med. 7, 313ra182 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Guan, J. et al. Therapeutic ligands antagonize estrogen receptor function by impairing its mobility. Cell 178, 949–963 e918 (2019).

Article  PubMed  CAS  Google Scholar 

O’Leary, B. et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 8, 1390–1403 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Turner, N. C. et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 21, 1296–1308 (2020).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Arnesen, S. et al. Estrogen receptor alpha mutations in breast cancer cells cause gene expression changes through constant activity and secondary effects. Cancer Res. 81, 539–551 (2021).

Article  PubMed  CAS  Google Scholar 

Nilsson, M. E. et al. Measurement of a comprehensive sex steroid profile in rodent serum by high-sensitive gas chromatography-tandem mass spectrometry. Endocrinology 156, 2492–2502 (2015).

Article  PubMed  CAS  Google Scholar 

Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78–83 (2017).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bach, K. et al. Differentiation dynamics of mammary epithelial cells revealed by single-cell RNA sequencing. Nat. Commun. 8, 2128 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Giraddi, R. R. et al. Single-cell transcriptomes distinguish stem cell state changes and lineage specification programs in early mammary gland development. Cell Rep. 24, 1653–1666 (2018).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Soares, E. & Zhou, H. Master regulatory role of p63 in epidermal development and disease. Cell Mol. Life Sci. 75, 1179–1190 (2018).

Article  PubMed  CAS  Google Scholar 

Gatti, V. et al. p63 at the crossroads between stemness and metastasis in breast cancer.Int. J. Mol. Sci. 20, 2683 (2019).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Visvader, J. E. & Stingl, J. Mammary stem cells and the differentiation hierarchy: current status and perspectives. Genes Dev. 28, 1143–1158 (2014).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wuidart, A. et al. Early lineage segregation of multipotent embryonic mammary gland progenitors. Nat. Cell Biol. 20, 666–676 (2018).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Keenan, A. B. et al. ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res. 47, W212–W224 (2019).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li, Z. et al. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nat. Commun 13, 2011 (2022).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jhaveri, K. L. et al. Phase Ia/b study of giredestrant ±palbociclib and ±luteinizing hormone-releasing hormone agonists in estrogen receptor-positive, HER2-negative, locally advanced/metastatic breast cancer. Clin. Cancer Res. 30, 754–766 (2024).

Article  PubMed  CAS  Google Scholar 

Risom, T. et al. Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. Cell 185, 299–310 (2022).

Article  PubMed  PubMed Central  CAS  Google Scholar 

DeRose, Y. S. et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17, 1514–1520 (2011).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sikora, M. J. et al. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer Res 74, 1463–1474 (2014).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li, S. et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 4, 1116–1130 (2013).

Article  PubMed  CAS  Google Scholar 

Nguyen, Q. H. et al. Profiling human breast epithelial cells using single cell RNA sequencing identifies cell diversity. Nat. Commun. 9, 2028 (2018).